ImmunoGen said Tuesday it will give partner Sanofi full rights to a set of experimental cancer treatments in exchange for $30 million, as the Waltham biotech continues to focus on its lead program for ovarian cancer.

ImmunoGen (Nasdaq: IMGN) said it had amended two previous licensing deals with Sanofi (NYSE: SNY) covering a total of five compounds, including a drug in Phase 3 development for multiple myeloma, another in a Phase 2 trial for breast cancer and two in Phase 1 trials. Under the re-worked…